Bio Sketch
Content
OGAN GUREL MD MPHIL
Biographical Sketch [email protected]
Dr. Gurel’s specific areas of expertise include medical education, business strategy development, organizational realignment, clinical transformation, innovation management and marketing strategy. His previous work experience includes the Aesis Group, Sg2 and Booz, Allen & Hamilton working with both large and small clients spanning the healthcare services, health insurance, biopharma and medical device sectors. BUSINESS BACKGROUND While at the Aesis Group, Ogan served as Chief Executive Officer at Duravest, Inc. – a publicly
traded holding company which focuses on convergent medical technologies. As VP and Medical Director at Sg2, LLC – a leading healthcare intelligence think-tank and consultancy serving hospitals and health systems - he led research teams providing thought leadership on topics such as, Surgical Services, Cancer Care, Cardiovascular Services, Procedure Centers, Imaging, Outpatient care, Neurosciences & Orthopedics, Payment & Finance, ICU, Emergency Departments, Hospital of the Future, Diabetes, and Asthma. Most notably, he was the principal architect and developer of the industryleading Impact of Change™ healthcare utilization forecasting system based on a unique differential equation model integrating demographic, sociocultural, financial and technology drivers to predict change. Dr. Gurel also served as clinical lead for strategy consulting projects at hospitals nation-wide, supported marketing and business development (helping to drive sales from startup to nearly $12M in three years) and represented the company for any clinical-facing functions. Prior to Sg2, Dr. Gurel was at the blue-chip management consultancy Booz, Allen & Hamilton engaged in a number of strategy projects for Fortune 500 healthcare and life sciences clients. During that time, he also completed the firm’s mini-MBA program. He has also served as an independent consultant to several medical device firms in which he was specifically involved with European (EMEA) and FDA clinical trial development, monitoring and oversight.
SCIENTIFIC & ACADEMIC BACKGROUND Dr. Gurel also has deep experience in the basic biomedical sciences holding a B.A.
cum laude in Biochemical Sciences from Harvard University after which he was a Visiting Researcher at the Institut LaueLangevin in Grenoble, France. During this time, he conducted NMR-based structural studies of DNA and neutron diffraction-based analyses of membrane protein structure. Dr. Gurel also holds an M.Phil. degree in Biochemistry & Molecular Biophysics from Columbia University where his research involved x-ray crystallographic structural studies of cytokines. His work has been published in the peer-reviewed scientific literature including the European Molecular Biology Organization (EMBO) Journal and the Journal of Molecular Biology. Additionally, he has conducted research in computer science winning 3rd place in the national Westinghouse (now Intel) Science Talent Search for work related to microprocessor software development systems. Dr. Gurel has taught a number of subjects - cellular and molecular biology, neuroanatomy, bioinformatics and mathematical modeling - at several universities including the Columbia University College of Physicians & Surgeons, Harvard Medical School and Roosevelt University and he is presently Adjunct Associate Professor of Bioengineering at the University of Illinois - Chicago.
CLINICAL BACKGROUND On the clinical side, Dr. Gurel received his M.D. with honors (Alpha Omega Alpha) from the
Columbia University College of Physicians & Surgeons and completed surgical internship at the Massachusetts General Hospital with a joint appointment as Clinical Fellow in Surgery at the Harvard Medical School. He is also experienced in international medical relief work during the Kosovo NATO military campaign as well as during the 1999 earthquake in Turkey. Dr. Gurel is fluent in French and German and has conversational ability in Russian.
THOUGHT LEADERSHIP & MEDIA As a healthcare technology expert and futurist, Dr. Gurel has been a frequent conference
speaker worldwide, addressing the issue of emerging technologies and their impact on the future of healthcare. His particular focus has been on convergent medical technologies including medical nanotechnology. Dr. Gurel’s commentaries have been published in prominent publications, including the Wall Street Journal and he is a regular columnist for Midwestbusiness.com, the Midwest’s most prominent technology newsletter, where he provides insight into emerging medical technologies. He is the host of the InTimeTV series “Insights in Medicine.”
Biographical Sketch [email protected]
Dr. Gurel’s specific areas of expertise include medical education, business strategy development, organizational realignment, clinical transformation, innovation management and marketing strategy. His previous work experience includes the Aesis Group, Sg2 and Booz, Allen & Hamilton working with both large and small clients spanning the healthcare services, health insurance, biopharma and medical device sectors. BUSINESS BACKGROUND While at the Aesis Group, Ogan served as Chief Executive Officer at Duravest, Inc. – a publicly
traded holding company which focuses on convergent medical technologies. As VP and Medical Director at Sg2, LLC – a leading healthcare intelligence think-tank and consultancy serving hospitals and health systems - he led research teams providing thought leadership on topics such as, Surgical Services, Cancer Care, Cardiovascular Services, Procedure Centers, Imaging, Outpatient care, Neurosciences & Orthopedics, Payment & Finance, ICU, Emergency Departments, Hospital of the Future, Diabetes, and Asthma. Most notably, he was the principal architect and developer of the industryleading Impact of Change™ healthcare utilization forecasting system based on a unique differential equation model integrating demographic, sociocultural, financial and technology drivers to predict change. Dr. Gurel also served as clinical lead for strategy consulting projects at hospitals nation-wide, supported marketing and business development (helping to drive sales from startup to nearly $12M in three years) and represented the company for any clinical-facing functions. Prior to Sg2, Dr. Gurel was at the blue-chip management consultancy Booz, Allen & Hamilton engaged in a number of strategy projects for Fortune 500 healthcare and life sciences clients. During that time, he also completed the firm’s mini-MBA program. He has also served as an independent consultant to several medical device firms in which he was specifically involved with European (EMEA) and FDA clinical trial development, monitoring and oversight.
SCIENTIFIC & ACADEMIC BACKGROUND Dr. Gurel also has deep experience in the basic biomedical sciences holding a B.A.
cum laude in Biochemical Sciences from Harvard University after which he was a Visiting Researcher at the Institut LaueLangevin in Grenoble, France. During this time, he conducted NMR-based structural studies of DNA and neutron diffraction-based analyses of membrane protein structure. Dr. Gurel also holds an M.Phil. degree in Biochemistry & Molecular Biophysics from Columbia University where his research involved x-ray crystallographic structural studies of cytokines. His work has been published in the peer-reviewed scientific literature including the European Molecular Biology Organization (EMBO) Journal and the Journal of Molecular Biology. Additionally, he has conducted research in computer science winning 3rd place in the national Westinghouse (now Intel) Science Talent Search for work related to microprocessor software development systems. Dr. Gurel has taught a number of subjects - cellular and molecular biology, neuroanatomy, bioinformatics and mathematical modeling - at several universities including the Columbia University College of Physicians & Surgeons, Harvard Medical School and Roosevelt University and he is presently Adjunct Associate Professor of Bioengineering at the University of Illinois - Chicago.
CLINICAL BACKGROUND On the clinical side, Dr. Gurel received his M.D. with honors (Alpha Omega Alpha) from the
Columbia University College of Physicians & Surgeons and completed surgical internship at the Massachusetts General Hospital with a joint appointment as Clinical Fellow in Surgery at the Harvard Medical School. He is also experienced in international medical relief work during the Kosovo NATO military campaign as well as during the 1999 earthquake in Turkey. Dr. Gurel is fluent in French and German and has conversational ability in Russian.
THOUGHT LEADERSHIP & MEDIA As a healthcare technology expert and futurist, Dr. Gurel has been a frequent conference
speaker worldwide, addressing the issue of emerging technologies and their impact on the future of healthcare. His particular focus has been on convergent medical technologies including medical nanotechnology. Dr. Gurel’s commentaries have been published in prominent publications, including the Wall Street Journal and he is a regular columnist for Midwestbusiness.com, the Midwest’s most prominent technology newsletter, where he provides insight into emerging medical technologies. He is the host of the InTimeTV series “Insights in Medicine.”
